No description
-
2018 (v1)PublicationUploaded on: April 14, 2023
-
2020 (v1)Publication
Cisplatin-containing salvage regimens followed by autologous hematopoietic stem cell (HSC) transplantation are the current standard of care for relapsed or refractory (R/R) lymphomas. We retrospectively analyzed efficacy and stem cell mobilizing activity of oxaliplatin, cytarabine, dexamethasone and rituximab (R-DHAOx) in 53 R/R diffuse large B...
Uploaded on: April 14, 2023 -
2024 (v1)Publication
CAR(-) CD4(+) T cell lymphopenia is an emerging issue following CAR-T cell therapy. We analyzed the determinants of CD4(+) T cell recovery and a possible association with survival in 31 consecutive patients treated with commercial CAR-T for diffuse large B-cell (DLBCL) or mantle cell lymphoma. Circulating immune subpopulations were...
Uploaded on: July 3, 2024